Author:
Duran George E.,Derdau Volker,Weitz Dietmar,Philippe Nicolas,Blankenstein Jörg,Atzrodt Jens,Sémiond Dorothée,Gianolio Diego A.,Macé Sandrine,Sikic Branimir I.
Funder
National Institutes of Health
Sanofi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference32 articles.
1. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JT, Fojo T et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125
2. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Cancer 31(2):277–283
3. Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U (2011) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65(1):40–45
4. Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X et al (2014) Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer 110:1958–1967
5. Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J et al (2015) Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14(1):193–201
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献